ArticleFrontiers in allergy2025
Risk factors for drug resistance in allergen immunotherapy for allergic rhinitis: a systematic review and meta-analysis.
Article in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allergen Immunotherapy (AIT) is largely considered to be the only therapy that can provide relief from allergic rhinitis (AR).Although its effectiveness has been confirmed by the results of a large number of practical studies such as randomized controlled trials, it may in some cases have a poor or no response to treatment due to the development of resistance under the influence of certain risk factors. The purpose of this Meta-analysis was to examine the risk factors for AR resistance to AIT treatment. Methods: A comprehensive literature search was conducted in PubMed, Embase, Web of Science, and Cochrane Library from inception to August 2025. Study quality was assessed using the NOS scale, AHRQ criteria, and the GRADE framework. Statistical analyses, performed with R 4.5.0 and Stata 14, employed fixed-or random-effects models to calculate pooled odds ratios (ORs) with 95% confidence intervals (CIs). Heterogeneity was explored via sensitivity analyses, and publication bias was evaluated using funnel plots with Begg and Egger tests. Results: A total of 12 studies involving 2,552 patients were included in this Meta-analysis. The results suggest that the following factors may be associated with AR resistance to treatment with AIT. Gender: male (OR = 1.53, 95% CI: 1.08-2.18); Specific diagnostic antibody aspects: s-IgE/t-IgE ratio (OR = 1.09, 95% CI: 1.02-1.16), sIgE, sIgG4; For cytokines: IL-10, IL-35, TGF-beta, IFN-gamma; On blood parameters: Eosinophil; Immune Cell Aspects:TH2/CD4, TFH2/CD4, CD23 + BNSM, CD23 + BSM, TFR/CD4, TFR/TFH2; Clinical/personal characteristics: demographics, disease severity, allergen type, treatment details, treatment adherence, symptom control, lung function, airway inflammation, inflammatory markers, immunologic markers, imaging markers, environmental and behavioral factors. With respect to the heterogeneity analysis, the heterogeneity of the other analyses was relatively low, except for age and t-IgE levels, where there was significant heterogeneity. Conclusion: The risk of developing resistance to AIT treatment for AR is closely associated with patient factors including gender, antibodies, cytokines, hematological parameters, clinical/personal characteristics, immune cells, and other indicators. Systematic Review Registration: PROSPERO CRD420251154551.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.